TriangleNCT05397171 · OUTCOME
Number of Participants With Positive Anti-drug Antibody (ADA) of AZD8853
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- From Day 1 up to 90 (±7 days) days after the last dose of AZD8853 (1 year)
What was measured
The immunogenicity of AZD8853 in participants with selected advanced/metastatic solid tumors were assessed. This outcome measure was assessed only for substudy 1 Part A.
Analysis population: Immunogenicity analysis set included all participants who received at least one dose of IP who have a non-missing baseline ADA result and at least 1 non-missing post-baseline ADA result.
Groups in this outcome
AZD8853 300 mg
Participants with advanced/metastatic solid tumors received AZD8853 300 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.
AZD8853 1000 mg
Participants with advanced/metastatic solid tumors received AZD8853 1000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.
AZD8853 3000 mg
Participants with advanced/metastatic solid tumors received AZD8853 3000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.
| Group | Source count |
|---|---|
| AZD8853 300 mg | 3 |
| AZD8853 1000 mg | 6 |
| AZD8853 3000 mg | 6 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| AZD8853 300 mg | 1 | Not reported | Not reported | Not reported | Not reported |
| AZD8853 1000 mg | 1 | Not reported | Not reported | Not reported | Not reported |
| AZD8853 3000 mg | 0 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 0
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 6
- group Id
- OG002
- value
- 6
- units
- Participants
- description
- The immunogenicity of AZD8853 in participants with selected advanced/metastatic solid tumors were assessed. This outcome measure was assessed only for substudy 1 Part A.
- groups
- description
- Participants with advanced/metastatic solid tumors received AZD8853 300 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.
- id
- OG000
- title
- AZD8853 300 mg
- description
- Participants with advanced/metastatic solid tumors received AZD8853 1000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.
- id
- OG001
- title
- AZD8853 1000 mg
- description
- Participants with advanced/metastatic solid tumors received AZD8853 3000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.
- id
- OG002
- title
- AZD8853 3000 mg
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- Immunogenicity analysis set included all participants who received at least one dose of IP who have a non-missing baseline ADA result and at least 1 non-missing post-baseline ADA result.
- reporting Status
- POSTED
- time Frame
- From Day 1 up to 90 (±7 days) days after the last dose of AZD8853 (1 year)
- title
- Number of Participants With Positive Anti-drug Antibody (ADA) of AZD8853
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice